StockNews.com Begins Coverage on NovaBay Pharmaceuticals (NYSE:NBY)

StockNews.com initiated coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY – Get Rating) in a research report issued on Saturday. The firm set a “hold” rating on the stock.

NovaBay Pharmaceuticals Price Performance

Shares of NovaBay Pharmaceuticals stock opened at $2.15 on Friday. The firm has a market cap of $4.04 million, a P/E ratio of -0.39 and a beta of 2.64. The firm has a 50 day simple moving average of $1.51 and a 200 day simple moving average of $0.66. NovaBay Pharmaceuticals has a fifty-two week low of $1.24 and a fifty-two week high of $12.96.

NovaBay Pharmaceuticals Company Profile

(Get Rating)

NovaBay Pharmaceuticals, Inc, a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands.